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Background/Aims: It has been known for at least 50 
years that alterations in methionine metabolism occur 
in human liver cirrhosis. However, the molecular basis 
of this alteration is not completely understood. In or- 
der to gain more insight into the mechanisms behind 
this condition, mRNA levels of methionine adenosyl- 
transferase (MATIA), glycine methyltransferase 
(GNAT), methionine synthase (MS), betaine homo- 
cysteine methyltransferase (BHMT) and cystathion- 
ine j?-synthase (CBS) were examined in 26 cirrhotic 
livers, five hepatocellular carcinoma (HCC) tissues 
and ten control livers. 
Methods: The expression of the above-mentioned 
genes was determined by quantitative RT-PCR analy- 
sis. Methylation of MATlA promoter was assessed by 
methylation-sensitive restriction enzyme digestion of 
genomic DNA. 
Results: When compared to normal livers MATlA, 
T” LIVER has the dual task of converting methion- ine, via S-adenosylmethionine (AdoMet) and S- 
adenosylhomocysteine (AdoHcy), into homocysteine, 
followed by reconversion of homocysteine into meth- 
ionine while feeding the transsulfuration pathway that 
leads to the formation from homocysteine of cysteine 
and glutathione (GSH) (Fig. 1). The two pathways are 
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GNMT, BHMT, CBS and MS mRNA contents were 
significantly reduced in liver cirrhosis. Interestingly, 
MATlA promoter was hypermethylated in the cir- 
rhotic liver. HCC tissues also showed decreased 
mRNA levels of these enzymes. 
Conclusions: These findings establish that the abun- 
dance of the mRNA of the main genes involved in 
methionine metabolism is markedly reduced in human 
cirrhosis and HCC. Hypermethylation of MATlA 
promoter could participate in its reduced expression 
in cirrhosis. These observations help to explain the 
hypermethioninemia, hyperhomocysteinemia nd re- 
duced hepatic glutathione content observed in cir- 
rhosis. 
Key words: Cirrhosis; DNA methylation; Hepatocar- 
cinema; Liver; Methionine. 
co-ordinated by AdoMet which inhibits the synthesis 
of methionine from homocysteine and activates cysta- 
thionine /3-synthase (CBS), the first step of the trans- 
sulfuration pathway (1,2). Moreover, AdoMet activates 
glycine N-methyltransferase (GNAT), an enzyme 
which accounts for about 1% of the hepatic cytosol(3), 
and whose main function is to remove excess AdoMet 
(1,2). The expression of GNAT betaine homocysteine 
methyltransferase (BHMT) and CBS is confined 
mainly to the liver, whereas the expression of methion- 
ine synthase (MS) occurs in all tissues (1,2). There are 
two genes coding for methionine adenosyltransferase 
(MAT), the enzyme that converts methionine into Ad- 
oMet, one (MATIA) expressed exclusively in the liver 
and a second gene (MAT2A) expressed in all tissues 
and fetal liver (4). As a consequence of this liver-speci- 
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fit expression of genes involved in methionine met- 
abolism, and although all tissues can synthesize and 
utilize AdoMet, the liver is the main place for the met- 
abolism of this amino acid. In humans, up to 85% of 
all methylation reactions and as much as 48% of meth- 
ionine metabolism occur in the liver (5). 
Human liver cirrhosis has been known to be associ- 
ated with alterations of methionine metabolism for at 
least 50 years (6). Many patients with alcoholic liver 
cirrhosis have increased serum methionine (68) and 
homocysteine (9), abnormal clearance of methionine 
after an oral load of this amino acid (7,8), and dimin- 
ished hepatic GSH content (10) and MAT activity 
(11,12). Methionine metabolism has also been investi- 
gated in various experimental models of liver disease. 
Ethanol and Ccl,-induced liver injury are associated 
with a reduction in hepatic AdoMet and an increase in 
AdoHcy, overall hepatic DNA hypomethylation, re- 
duced hepatic GSH content, and increased serum 
homocysteine (13-18). The importance of this alter- 
ation in the metabolism of methionine for the pro- 
gression of the disease has been substantiated by the 
numerous publications showing in experimental 
models that AdoMet administration reduces liver dam- 
age induced by a variety of agents (15-23), and by the 
recent finding demonstrating that AdoMet treatment 
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Fig. 1. Liver methionine cycle und transsulfuration path- 
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improves survival in patients with alcoholic liver cir- 
rhosis (24). However, knowledge of the molecular basis 
of this alteration of methionine metabolism in human 
liver cirrhosis and of the mechanism of action of Ad- 
oMet is limited. Thus we have examined the mRNA 
level of MATlA, GNM?; MS, BHMT and CBS in 26 
cirrhotic livers, five hepatocellular carcinoma (HCC) 
tissues and ten control liver tissues. 
Materials and Methods 
Patients 
We have studied a group of 26 patients (17 males and 9 females, mean 
age 54+8.5 years) with liver cirrhosis of different etiology (13 HCV 
cirrhosis. 10 alcoholic cirrhosis, one HBV cirrhosis, one cryptogenetic 
cirrhosis and one primary biliary cirrhosis. PBC). The control group 
for the cirrhotic patients consisted of 10 subjects in whom a cholecys- 
tectomy was performed for the treatment of a symptomatic cholelithi- 
asis and who consented to be submitted to a liver biopsy during the 
surgical procedure. Liver samples were immediately frozen and kept 
at -80°C until processed. In the subjects from the control group, 
both the liver function tests and the liver biopsy were normal. This 
study was approved by the human research review committee of the 
University of Navarra. Hospital Clinic and Hospital Principe de As- 
turias. Cancerous liver tissues were obtained from five liver patients 
undergoing surgical resection for primary HCC (25). The contami- 
nation of HCC samples wsith noncancerous tissue was less than 5% 
as determined by histopathology. The control group for the HCC 
patients consisted of normal liver tissue obtained from normal liver 
included in the resected liver specimens of six patients with metastatic 
colon or breast carcinoma. We were blinded to the clinical character- 
istics (whether there was hepatitis B or C. etc.). This was mandated 
by the Institutional Review Board of the University of Southern Cali- 
fornia School of Medicine. from where these liver specimens were 
obtained. These tissues were immediately frozen in liquid nitrogen for 
subsequent isolation of RNA. Written informed consent was ob- 
tained from each patient. The study was approved by University of 
Southern California School of Medicine‘s human research review 
committee. 
R T- PCR sttrciks 
Total RNA was extracted from liver biopsies as previously described 
(25). Aliquots of 2 ,“g were reverse transcribed using M-MLV Reverse 
Transcriptase (Gibco Life Technologies, MD, USA) and subsequently 
amplified by polymerase chain reaction (PCR) using the BioTaq DNA 
Polymerase (Bioline. UK). The primers used for the different genes 
studied were: 5’-ATG TCA CCC GCG CTC CAA GAC-3’ and 5’- 
TCC AGA AGT CCT TTG GCC TGC-3’ for MS. 5’-GTC ATG 
CAG ACC TTC ACC TTC TA-3’ and 5’CTC CTT CAT GAG CTT 
CAC TG-3’ for BHM7: 5’-ACA TGA CCA AGT TCC TGA GC-3’ 
and 5’-GCC ACG AAG ‘TTC AGC AAG TC-3’ for CBS. 5’-AAG 
AGG GCT TCA GTG TGA CG-3’ and 5’-AGG CTT GAA GTC 
GCC CAG GA-3’ for G:VMZ 5’-TCT CCT CCA GCG TGA TG-3’ 
and S’-GTT CAC ATC GGA GTC TG for MAT/A and 5’-.4TG 
AAG TGG GTA ACC-3’ and 5’-TAT CAG CPIG CTT GGC-3’ for 
HSA. To avoid amplification of genomic DNA which could contami- 
nate our RNA preparations, these primers were designed tlankiug 
intronic sequences. 18s rRNA was simultaneously amplified using the 
Alternate 18s Internal Standards primers set (Ambion. TX. USA) 
and served as an internal loading control. Reactions were resolved in 
a 2% agarose gel, stained with ethidium bromide and quantitated 
using the Molecular Analyst software (Bio-Rad. Hercules. CA, USA). 
The lOO-bp DNA Ladder molecular weight standards from Gibco 
Life Technologies were used. 
DNA estruction and Southern blot anul_vsis 
Genomic DNA was prepared from control and cirrhotic liver samples 
as described previously (26). Aliquots of high molecular weight DNA 
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(10 pg) were digested to completion with DraI and then either MspI 
or HpaII restriction enzymes (Boehringer Mannheim, Mannheim, 
Germany). After digestion, samples were loaded on agarose gels, elec- 
trophoresed and blotted onto NYTRAN membranes (Schleicher & 
Schuell, Keene NH, USA). Hybridizations were carried out with a 
0.89 kb probe derived from the human MATIA promoter (DraI-DraI 
fragment encompassing from nucleotide -589 to - 1479) (27) labeled 
with [a-32P]dCTP (3000 Ci/mmol, Amersham, Little Chalfont, UK) 
by random priming using the Megaprime DNA labeling system 
(Amersham) as reported (26). Membranes were then exposed to X- 
ray films. 
RNA extraction and Northern blot analysis 
Total RNA was extracted from control livers and HCC samples by 
the guanidinium thiocyanate method as previously described (25). 
Aliquots (20 pg) of total RNA were electrophoresed, blotted, prehy- 
bridized and hybridized as described (25). The probes (25) were 
labeled with [c+~~P] dCTP (3000 Ci/mmol, Amersham, Little Chal- 
font, UK) by random priming using the Megaprime DNA labeling 
system (Amersham). Equal loading of the gels was assessed by hy- 
bridization with an 18s ribosomal RNA probe. Quantitation was per- 
formed by scanning densitometry of the x-ray films. 
Serum methionine and total homocysteine (tHcy) determination 
Serum methionine was determined as described (17). Total serum 
homocysteine (tHcy) was measured as reported (28), with the modifi- 
cations described in Deulofeu et al. (29). 
Statistics 
All data are means?SEM. The Mann-Whitney unpaired test was 
used to compare groups. 
Cirrhotics 
c 1 2 3 
Results 
Reduced mRNA levels of the main enzymes involved in 
methionine metabolism in cirrhotic livers 
We assessed MATlA mRNA levels by RTPCR in 26 
cirrhotic and ten normal livers (Fig. 2). Only three cir- 
rhotic livers (11%) showed MAT1 A mRNA abundance 
comparable to that measured in normal livers. De- 
creased MATIA mRNA content in liver was observed 
in 15 cirrhotic livers (58%). In eight cirrhotic patients 
(31%) hepatic MATlA mRNA level was very low or 
non-detectable. MAT2A expression was not induced in 
any of the cirrhotic patients (not shown). We also as- 
sessed GNMT MS, BHMT and CBS mRNA content 
in the same cirrhotic and normal livers by RTPCR 
(Fig. 2). GNMT MS, BHMT and CBS mRNA was 
very low or undetectable in the majority of the cir- 
rhotic samples (54%, 65%, 69% and 58%, respectively). 
The percent of cirrhotic livers showing reduced mRNA 
abundance for GNMT MS, BHMT and CBS was 42%, 
35%, 19% and 15%, respectively. In the case of GNMT, 
BHMT and CBS, one, three and seven patients, respec- 
tively, showed mRNA levels similar to those deter- 
mined in normal livers. None of the cirrhotic livers 
Cirrhotics Cirrhotics 
C 1 2 3 c 1 2 
MATlA MS 
18s 18s 
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31% 68% 11% 
Cirrhotics 
CBS 
18s 
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69% 19% 11% 
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c 1 2 3 
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68% 15% 27% 
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Fig. 2. Expression of methionine metabolism genes in the liver of cirrhotic and control patients. C: normal livers (controls). 
Cirrhotics were divided into three groups according to the levels of expression of the diff erent genes tested: group 1: patients 
with very low or non-detectable xpression, group 2: patients with a level of expression lower than controls, group 3: patients 
with a level of expression similar to controls. The number of patients per group is indicated for each gene analyzed. Serum 
albumin (I-ISA) expression in control and cirrhotic patients is also shown. Representative RT-PCR reactions are shown for 
the 26 patients and 10 normal livers. 18s ribosomal RNA was used as internal control. The left lane of each gel shows the 
molecular weight markers, the most intense band corresponds to 600 bp. 
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showed b1.Y mRNA levels comparable to those meas- 
ured in normal livers. Human serum albumin (HSA) 
mRNA level was normal in 50% of the cirrhotic livers, 
reduced in 31% of the tissues, and very low or non- 
detectable in 19% of the samples (Fig. 2). Patients with 
a marked reduction in the expression of a given gene 
(group one) tended to be in this same group for all 
genes tested. For instance, out of the 14 patients in 
group one for GNMT (Fig. 2), the same 14 patients 
were in group one for BHMT, 12 in group 1 for CBS 
and 11 in group 1 for MS. The percent of livers with 
very low or non-detectable levels of mRNA for the 
various genes of methionine metabolism analyzed was 
higher for tissues from patients with HCV cirrhosis 
than with alcoholic cirrhosis (Fig. 3). 
In order to evaluate if the reduced expression of the 
various genes involved in methionine metabolism was 
related to the severity of the disease, expressed as the 
Child-Pugh score (30), patients were divided into two 
groups. One group (group 1) included patients show- 
ing normal or only reduced levels of mRNA for at least 
three of the five genes analyzed involved in methionine 
metabolism. The second group (group 2) included 
those patients with very low or undetectable levels of 
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mRNA for all or four of the five genes analyzed in- 
volved in methionine metabolism. The mean value for 
the Child-Pugh score was significantly higher in the cir- 
rhotic patients in group 2 (9.0~0.7) than in the cir- 
rhotic patients in group 1 (7.120.4, ~~0.03). 
The mean value for tHcy was significantly higher in 
the cirrhotic patients in group 2 (17.0+2.0 ,uM) than 
in group 1 (12.0~ 1.6 ,uM, p<O.O5). In agreement with 
previous results (9), the tHcy concentration in our 
group of cirrhotics (14.1 t 1.3 PM) was significantly 
higher than in the control group (8.140.9 ,LIM, 
pcO.03). In agreement with previous publications (6- 
8), fasting serum methionine in cirrhotics (106.3134.7 
,uM) was higher than in the control group (30.X+4.8 
,LM, p<O.Ol). Differences in methionine concentration 
in cirrhotic patients in groups 1 (46.228.6 LIM) and 2 
(171.8t68.1 ELM, /~0.01) were also statistically sig- 
nificant. 
Reduced mRNA levels qf the main enzymes involved in 
methionine metabolism in HCC tissues 
We have reported a switch in gene expression from 
MA TIA to MAT2A in various human-derived cancer 
cell lines and HCC tissues resected from patients (25). 
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Fig. 3. Expression of liver methionine metabolizing genes and serum albumin (HSA) in cirrhotic patients according to the 
etiology of the disease: HCV cirrhosis or alcoholic cirrhosis. Patient groups are as d@ed in the legend to Fig. 2. the 
percentage of patients in each group is shown. 
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As expected, in the five HCC tissues used in the present 
experiments the mRNA content of MAT2A increased 
about 6-fold in respect o the average control liver (Fig. 
4A) and in HCC tissues MATlA mRNA content was 
very low or non-detectable (not shown). We next exam- 
ined the mRNA abundance by RT’-PCR of the main 
enzymes of methionine metabolism in these HCC 
tissues. BHMT, CBS, GNMT and MS mRNA content 
was markedly decreased in HCC tissues compared with 
normal liver (Fig. 4B). The average mRNA abundance 
of BHMT CBS, GNMT and MS in HCC tissues was 
48%, 25%, 34% and 35%, respectively, of that deter- 
mined in normal liver. 
Hypermethylation of hepatic MATIA promoter in 
human cirrhosis 
We have recently reported evidence showing that 
MATlA silencing during liver transformation is me- 
A 
B 
Normal liver HCC 
1234512345 
MAT2A mRNA 
Normal liver HCC 
12345612345 
- CBS 
- 18s 
- MS 
- 18s 
Fig. 4. A. Expression of MATZA in human hepatocarcino- 
ma tissues and normal liver tissues as analyzed by Northern 
blotting. Hybridization with a 18 S rRNA probe was car- 
ried out as loading control. B. Expression of BHMT, CBS, 
GNMT and MS in human hepatocarcinoma tissues and 
normal liver tissues as analyzed by quantitative RT-PCR 
l&S ribosomal RNA was used as internal control. Samples 
and controls are as described in Materials and Methods. 
diated by methylation of the gene promoter and histone 
deacetylation (26). Additionally, we have observed that 
MATlA promoter is hypermethylated in livers from 
CCld-induced cirrhotic rats (26). MATlA promoter 
methylation was assessed in ten cirrhotics (five with 
HCV cirrhosis and five with alcoholic cirrhosis) and five 
normal livers by methylation-sensitive restriction en- 
zyme analysis as described in Materials and Methods. 
Fig. 5 shows a representative experiment with the results 
of MATlA promoter methylation obtained in two nor- 
mal livers, two alcoholic and two HCV cirrhotic livers. 
The probe used in this study corresponds to a 0.89 kb 
DraI-DraI fragment (nucleotides - 589 to - 1479) of the 
human MATIA promoter (27) which contains a single 
MspIIHpaII restriction site (located at position -737). 
As can be observed in Fig. 5, digestion of control liver 
samples with DraI and either MspI or HpaII yields one 
fragment of 0.74 kb which is recognized by this probe. 
In cirrhotic liver samples, after DraI treatment, MspI di- 
gestion generated the same 0.74 kb band present in con- 
trol samples. However, HpaII treatment yielded a 0.89 
kb band, indicating that this enzyme did not cut and 
thus that MATlA promoter is hypermethylated at this 
site. MA Tl A promoter methylation was increased in the 
liver from all cirrhotic patients assessed independently 
of the etiology of the disease. 
-1800 -1600 -1400 -1200 -1wJ -800 -6m -400 -200 +l 
I I I I I I I I I I 
I+ 
Normal liver Cirrhotic liver 
HCV Alcoholics 
MHMHMHMHMHMH ------ 
- 0.89 kb 
- 0.74 kb 
Fig. 5. Methylation status of MATlA 5’ region in normal 
liver and cirrhotic liver tissue. Restriction map of MATlA 
promoter indicating the location of the MspZZHpaZZ restric- 
tion site and the 0.88 kb DraZ-DraZ probe used in this 
analysis. Lower panel shows a representative Southern blot 
analysis of genomic DNA from normal, HCV and alcoholic 
cirrhotic liver after digestion with DraZ and MspZ (M) or 
HpaZZ (H) performed with the probe described above. The 
molecular size of the bands detected with this probe is indi- 
cated. 
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Discussion 
Our results show that the alterations of methionine 
metabolism in human liver cirrhosis can be ascribed to 
a marked reduction in the abundance of the mRNA of 
the main enzymes involved in the metabolism of this 
amino acid. Although not measured in the present 
work, the corresponding enzyme protein levels are 
likely to be reduced in a chronic situation such as liver 
cirrhosis. The reduction in MATIA mRNA content 
can explain the previously described increase in serum 
methionine (6,7) and abnormal clearance of methion- 
ine after an oral load of this amino acid (7) observed 
in patients with liver cirrhosis of different origins. In 
agreement with previous results (9) we observed an 
increase in tHcy in cirrhosis, which could be explained 
by the deficiencies in both cystathionine synthesis and 
homocysteine remethylation in the liver of these pa- 
tients caused by the reduced abundance of CBS, MS 
and BHMT mRNA. In the liver, homocysteine may 
potentiate the fibrogenic effect of other agents such as 
ethanol and cytokines. Thus, we have recently shown 
that homocysteine is able to induce the expression of 
tissue inhibitor metalloproteinase-1 (TIMP-1) and 
al(I) procollagen in rat hepatic stellate cells (31). The 
reduced content of CBS mRNA and the consequent 
deficiency of cystathionine synthesis could also explain 
the reduced content of hepatic GSH (I 0), plasma taur- 
ine (8) and urinary sulfate (7) in human liver cirrhosis. 
It has been previously demonstrated that in cirrhotic 
patients methionine clearance (8) and tHcy levels in 
plasma (9) correlate with the degree of liver dysfunc- 
tion as determined by the Child-Pugh score. Accord- 
ingly, this work shows that in those patients with more 
severe disease, expressed as the Child-Pugh score, the 
expression of the main genes involved in methionine 
metabolism was more compromised. 
Impairment of the metabolism of methionine in rats 
by feeding a diet deficient in choline, Blz, folate and 
methionine leads to an enhancement of chemically-in- 
duced hepatocarcinogenesis (32) and to the spon- 
taneous appearance of these cancers (33,34). These 
facts support the existence of a strong link between a 
defective one-carbon metabolism in liver and the devel- 
opment of neoplasia. A significant number of cirrhotic 
patients, especially those with HCV infection, develop 
HCC. In this regard the cirrhotic liver can be con- 
sidered as a precancerous condition (35,36). The pres- 
ent observation showing that the mRNA content of 
MS and BHMT is reduced or non-detectable in a large 
majority of cirrhotic patients (only three cirrhotics had 
normal levels of BHMT mRNA and none of them had 
normal levels of MS mRNA), suggests that this defect 
in the remethylation of homocysteine may contribute 
to the development of HCC in cirrhosis. 
In HCC tissues the mRNA content of GNM7: 
BHM7: hfS and CBS was markedly diminished with 
respect to normal liver and, and as previously de- 
scribed (25), a switch in gene expression from MATIA 
to MAT2A was observed. This indicates that the meth- 
ionine cycle and the transsulfuration pathway are both 
operating in HCC tissues; however, the capacity of 
these two pathways is markedly diminished as com- 
pared to that of a normal liver. First. while the prod- 
ucts of MATIA are two MAT isoenzymes with high 
capacity to remove methionine from serum, the prod- 
uct of MATJA is an enzyme with high affinity but low 
capacity to metabolize this amino acid (1,4). Second, 
the reduced abundance of the mRNA of CBS, BHMT 
and MS (25%, 48’!% and 35X, respectively, of that in 
normal liver) indicate a reduced capacity of the HCC 
tissue to catabolize homocysteine coming to the liver 
from other tissues and an impaired transsulfuration 
pathway as compared to that of normal liver. This re- 
duced capacity to remethylate homocysteine, due to 
impaired expression of MS and BHM7; may explain 
the relative methionine dependence reported for trans- 
formed hepatic cells (37). In addition, the concomitant 
reduction in CBS expression, leading to elevated 
homocysteine levels, contributes to explain the in- 
creased production of homocysteine thiolactone, a 
highly reactive form of homocysteine (38), by trans- 
formed cells (39). Despite these deficiencies. the activ- 
ity of the methionine cycle in HCC is probably suf- 
ficient to sustain the tumor necessities of AdoMet, 
methionine (through remethylation of homocysteine), 
folate cycling, choline metabolism and GSH content. 
Additionally, these changes in the pattern of expression 
of methionine metabolizing enzymes reflect the dedif- 
ferentiation of the hepatocarcimoma cell. and thus 
may be of diagnostic or prognostic value. 
The finding that MATIA promoter is hypermethyl- 
ated in human liver cirrhosis, in an environment of glo- 
bal DNA hypomethylation (37), and our previous ob- 
servations (26,40) showing that silencing of MATZA is 
mediated by methylation of the gene and histone de- 
acetylation, suggest that the reduced abundance of the 
mRNA of the enzymes involved in methionine met- 
abolism in cirrhosis is the result of an active process 
and not only the consequence of an overall reduction 
of hepatic gene transcription. MA T/A promoter was 
hypermethylated in the cirrhotic patients indepen- 
dently of the etiology of the disease, and as we reported 
previously in a rat model of CC],-induced cirrhosis 
(26) these observations indicate that this process can 
912 
be triggered under liver-damaging conditions, indepen- 
dently of the noxious agent. 
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